Use of valtrin in the preparation of an anti-mycobacterium tuberculosis drug
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- BEIJING CHEST HOSPITAL CAPITAL MEDICAL UNIV
- Filing Date
- 2025-10-14
- Publication Date
- 2026-06-09
AI Technical Summary
Existing anti-tuberculosis drugs have long treatment durations, significant side effects, and poor patient compliance. Multidrug-resistant tuberculosis has a low cure rate, and the development of new and effective drugs is progressing slowly, leading to severe challenges in tuberculosis treatment.
Valepotriate was used as the active ingredient to prepare an anti-tuberculosis drug. Its killing and antibacterial effects against Mycobacterium tuberculosis were verified through in vitro and in vivo experiments. The drug was then formulated with pharmaceutically acceptable excipients.
Valerianin exhibits significant anti-tuberculosis activity, has low cytotoxicity, and can effectively kill Mycobacterium tuberculosis, providing a new direction for the development of anti-tuberculosis drugs.
Smart Images

Figure CN120919098B_ABST